Deleted Tweets From Scott Gottlieb, R-D.C.

My statement on #FDA’s comprehensive campaign to confront the crisis of opioid abuse and misuse; and some new steps that the agency will be taking this fall: https://t.co/v50AHA2yEY https://t.co/KqKO4TBTvS

#FDA will continue to issue updates as we investigate the root cause of the valsartan impurity; we issued a comprehensive statement on our progress to date and the operation we have underway to find the cause, and prevent a recurrence of this episode. https://t.co/nozFGT0vmZ https://t.co/21oL6mwLZA

RT @LyndsayMMeyer: At the biosimilars meeting and Dr. Sherman wants @SGottliebFDA to know she's just said something nice about him. No… https://t.co/i2yoGk96Ay

RT @US_FDA: The new school year has begun! Healthy breakfasts are a must for kids and help keep them going strong all day. Skip… https://t.co/ZOv8brKSmg

Congratulations to this year’s graduating class of #FDA Commissioner’s Fellows. We’re in deep appreciation of their work and grateful for their many contributions toward enhancing FDA’s regulatory science and advancing our public health programs. https://t.co/LG1JQIQDAl

BACK TO SCHOOL: Did you know lunch boxes should be washed with hot soapy water after each use? To make sure lunches and snacks are safe for those you pack for, you should follow our recommendations here https://t.co/EOLB7kbTec https://t.co/dkQXz0xOnF

Intense uncertainty can be the hardest part of a grave medical diagnosis. Physical health is inextricably linked to the emotional aspects of illness. This poignant piece from @statnews captures these struggles. https://t.co/7iTf74V2Uc

1/2 Heads up to all developers, Sept. 30 is the deadline to submit a proposal for #FDA’s innovation challenge to spur development of medical devices ‒ including digital health technologies and diagnostic tests ‒ that target pain, addiction and diversion: https://t.co/CJUxjGsadU

Access is a matter of public health. Facilitating dialogue between device makers and payors during planning phase of clinical trials can expedite patient access to safe, effective devices; esp. through collection of clinical evidence that informs regulatory and coverage decisions

In today’s FDA Voice Blog, I highlight our work to help address a potential road block to timely patient access to medical devices – payor coverage decisions. We want to be a partner in helping facilitate efficient access to beneficial innovations https://t.co/GotI5I7yaH

Patients may not have access to an #FDA approved or cleared device in the absence of adequate coverage. That’s why we’re expanding our work with private payors to help narrow the time it takes for payors to make a coverage determination on new medical devices

2/2 Medical devices have the potential to play a novel role in tackling the opioid crisis through new ways to detect, treat/prevent addiction, address diversion and treat pain. #FDA’s committed to an all-of-the-above approach to confront this epidemic: https://t.co/2vYePOcRNV

RT @FDAOncology: Tomorrow, Sept. 6 in person or online: FDA-AACR Workshop on Non-clinical Models for Safety Assessment of Immuno-onc… https://t.co/ZKGydeM9r4

We’ll also be releasing a “Quik Review” pilot where we expect to reduce our device center’s review time for certain well understood, lower-risk 510(k) submissions by as much as 30%. https://t.co/0x3WbFhGLU

We’re committed to protecting patients by minimizing significant uncertainties in medical devices, w/o delaying access to innovation. New Guidance describes factors #FDA uses to evaluate uncertainty, when applying gold standard for safety, effectiveness https://t.co/IIRBP0uFi8

@SarahKarlin >10% first cycle approvals for genetics is a big improvement BUT this is a big area of focus and room for improvement. Many apps eventually get approved so the cycling drains resources, delays access. Getting rate of first cycle approvals up is key goal for how we☝️competition

Today at Medical Device Innovation Consortium Annual Public Forum, I gathered with stakeholders to announce new #FDA initiatives: expanding payor coverage discussions, clarifying our approach to benefit risk decisions in innovative med tech. https://t.co/0x3WbFhGLU

RT @RAPSorg: .@US_FDA Reveals How #Manufacturing Facilities are Prioritized for Inspections | #Regulatory Focus… https://t.co/oOl3bUDSzf

#FDA is launching a pilot program, Quik Review, that’ll help us evaluate whether we can modernize the premarket submission process for medical devices, by allowing applicants to submit information to us using a new, more streamlined electronic format. https://t.co/1FlD08IK3K

RT @FDAfood: #OUTBREAK update. Today @CDCgov announced the #Salmonella outbreak associated with Hy-Vee Pasta Salad appears to b… https://t.co/kWdiy8ZecN

My statement on #FDA’s comprehensive campaign to confront the crisis of opioid abuse and misuse; and some new steps that the agency will be taking this fall: https://t.co/v50AHA2yEY https://t.co/KqKO4TBTvS

#FDA will continue to issue updates as we investigate the root cause of the valsartan impurity; we issued a comprehensive statement on our progress to date and the operation we have underway to find the cause, and prevent a recurrence of this episode. https://t.co/nozFGT0vmZ https://t.co/21oL6mwLZA

RT @LyndsayMMeyer: At the biosimilars meeting and Dr. Sherman wants @SGottliebFDA to know she's just said something nice about him. No… https://t.co/i2yoGk96Ay

RT @US_FDA: The new school year has begun! Healthy breakfasts are a must for kids and help keep them going strong all day. Skip… https://t.co/ZOv8brKSmg

Congratulations to this year’s graduating class of #FDA Commissioner’s Fellows. We’re in deep appreciation of their work and grateful for their many contributions toward enhancing FDA’s regulatory science and advancing our public health programs. https://t.co/LG1JQIQDAl

BACK TO SCHOOL: Did you know lunch boxes should be washed with hot soapy water after each use? To make sure lunches and snacks are safe for those you pack for, you should follow our recommendations here https://t.co/EOLB7kbTec https://t.co/dkQXz0xOnF

Intense uncertainty can be the hardest part of a grave medical diagnosis. Physical health is inextricably linked to the emotional aspects of illness. This poignant piece from @statnews captures these struggles. https://t.co/7iTf74V2Uc

1/2 Heads up to all developers, Sept. 30 is the deadline to submit a proposal for #FDA’s innovation challenge to spur development of medical devices ‒ including digital health technologies and diagnostic tests ‒ that target pain, addiction and diversion: https://t.co/CJUxjGsadU

Access is a matter of public health. Facilitating dialogue between device makers and payors during planning phase of clinical trials can expedite patient access to safe, effective devices; esp. through collection of clinical evidence that informs regulatory and coverage decisions

In today’s FDA Voice Blog, I highlight our work to help address a potential road block to timely patient access to medical devices – payor coverage decisions. We want to be a partner in helping facilitate efficient access to beneficial innovations https://t.co/GotI5I7yaH

Patients may not have access to an #FDA approved or cleared device in the absence of adequate coverage. That’s why we’re expanding our work with private payors to help narrow the time it takes for payors to make a coverage determination on new medical devices

2/2 Medical devices have the potential to play a novel role in tackling the opioid crisis through new ways to detect, treat/prevent addiction, address diversion and treat pain. #FDA’s committed to an all-of-the-above approach to confront this epidemic: https://t.co/2vYePOcRNV

RT @FDAOncology: Tomorrow, Sept. 6 in person or online: FDA-AACR Workshop on Non-clinical Models for Safety Assessment of Immuno-onc… https://t.co/ZKGydeM9r4

We’ll also be releasing a “Quik Review” pilot where we expect to reduce our device center’s review time for certain well understood, lower-risk 510(k) submissions by as much as 30%. https://t.co/0x3WbFhGLU

We’re committed to protecting patients by minimizing significant uncertainties in medical devices, w/o delaying access to innovation. New Guidance describes factors #FDA uses to evaluate uncertainty, when applying gold standard for safety, effectiveness https://t.co/IIRBP0uFi8

@SarahKarlin >10% first cycle approvals for genetics is a big improvement BUT this is a big area of focus and room for improvement. Many apps eventually get approved so the cycling drains resources, delays access. Getting rate of first cycle approvals up is key goal for how we☝️competition

Today at Medical Device Innovation Consortium Annual Public Forum, I gathered with stakeholders to announce new #FDA initiatives: expanding payor coverage discussions, clarifying our approach to benefit risk decisions in innovative med tech. https://t.co/0x3WbFhGLU

RT @RAPSorg: .@US_FDA Reveals How #Manufacturing Facilities are Prioritized for Inspections | #Regulatory Focus… https://t.co/oOl3bUDSzf

#FDA is launching a pilot program, Quik Review, that’ll help us evaluate whether we can modernize the premarket submission process for medical devices, by allowing applicants to submit information to us using a new, more streamlined electronic format. https://t.co/1FlD08IK3K

RT @FDAfood: #OUTBREAK update. Today @CDCgov announced the #Salmonella outbreak associated with Hy-Vee Pasta Salad appears to b… https://t.co/kWdiy8ZecN